국소 진행된 직장암의 수술전 방사선 조사시 5 Fluorouracil 경정맥주사와 경구용 Doxifluridine 복용의 전향적 비교 연구
Prospective Randomized Trial Comparing Intravenous 5 Fluorouracil and Oral Doxifluridine as Preoperative Concurrent Chemoradiation for Locally Advanced Rectal Cancer
김남규, 박재균, 윤성현, 노재경, 민진식, 성진실,
소속 상세정보
김남규 ( Kim Nam-Kyu )
연세대학교 의과대학 외과학교실
박재균 ( Park Jea-Kun )
연세대학교 의과대학 외과학교실
윤성현 ( Yun Seong-Hyeun )
연세대학교 의과대학 외과학교실
노재경 ( Noh Jae-Kyung )
연세대학교 의과대학 종양내과학교실
민진식 ( Min Jin-Sik )
연세대학교 의과대학 외과학교실
성진실 ( Seong Jin-Sil )
연세대학교 의과대학 방사선종양학교실
KMID : 0356720000160060469
Abstract
Purpose: Preoperative radiation treatment with concomittant intravenous infusion of 5-fluorouracil has been known to be effective in shrinking and downstaging the tumor. Treatment with Doxifluridine (synthetic 5-deoxynucleoside derivative) medication prolongs drug exposure to tumor tissue, so it can be considered synergistic to concurrent radiotherapy. Intravenous 5-FU and oral Doxifluridine were compared with respect to tumor response, toxicity, and quality of life of patients.
Methods: Twenty eight patients with rectal cancer, staged as over T3N1 or T4 by transrectal ultrasonography between July 1997 and December 1998 were included. Intravenous 5-FU (450 mg/m2/day) and leucovorin (20 mg/m2) was given for five consecutive days during first and fifth weeks of irradiation therapy (50.4 Gy) (N=14). Oral Doxifluridine (700 mg/m2/day) and leucovorin (20 mg/m2) was given daily during radiation treatment (N=14). Quality of life was scored according to twenty two activity items (good: ＞77, fair: ＞58, poor: ＜57). Surgical resection was performed four weeks after completion of concurrent chemoradiation treatment. Tumor response was classified as CR (Complete Response), PR (Partial Response: 50% diminution of tumor volume or downstaging), or NR (No Response).
Results: Tumor response was CR: 3/14 (21.4%), PR: 7/14 (50%) and NR: 4/14 (28.6%) in IV arm versus CR: 2/14 (14.2%), PR: 6/14 (42.9%) and NR: 6/14 (42.9%) in oral arm (p=0.16, 0.23, 0.24, respectively). Quality of life was poor (36.4% vs 33.3%), fair and good (63.6% vs 66.7%, respectively) between IV arm and oral arm. Systemic recurrence during follow up periods was 1/14 (7.1%) in IV arm and 2/14 (14.3%) in oral arm, respectively (p=0.307). One local recurrence was observed in oral arm. Hematologic toxicity was 3/14 (21.4%) in IV arm versus 4/14 (28.5%) in oral arm, respectively. Gastrointestinal toxicity was 2/14 (14.3%) versus 5/14 (35.7%) and stomatitis was observed in IV arm (1/14, 7.1%)
Conclusion: Oral doxifluridine based chemotherapy shows a comparable tumor response and oncologic results, but there was no benefits as far as quality of life and toxicity were concerned.
키워드
직장암;수술 전 방사선 및 항암약물 병합치료
5 Fluorouracil;Rectal cancer;Preoperative chemoradiation;Intravenous 5 fluorouracil;Oral doxifluridine
원문 및 링크아웃 정보
등재저널 정보